Deal or Case news
01.04.2021 5 min read
On 29 March, LAVA Therapeutics B.V. (Nasdaq: LVTX) closed its IPO on the Nasdaq Global Market, raising approximately USD 100 million in gross proceeds. The Underwriters on this IPO are J.P. Morgan Securities LLC, Jefferies LLC, SVB Leerink LLC and Kempen & Co U.S.A., Inc.

NautaDutilh acted as Dutch counsel to LAVA Therapeutics, alongside Cooley LLP (US counsel). 

LAVA Therapeutics has its headquarter in Utrecht and was founded in 2016. It is a biotechnology company focused on developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells. 

‘NautaDutilh is proud to have been able to help LAVA Therapeutics reach this important milestone’ says team lead Paul van der Bijl. 

The NautaDutilh team further included Nina Kielman, Dewi Walian, Niek de Kort, Sanne Mesu, Jeroen Boelens, Terrence Dom and Peter Vogels.

For press release and media attention, please see:

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.